Long-Term Effects of Mobithron Advance on Knee Osteoarthritis Aims to Investigate the Effects of Mobithron Advance on OA Progression
Key facts
- Where
- Kota Bharu, MalaysiaSee the site
- Phase
- Early phase 1
Where in Malaysia
- Hospital Univerisiti Sains Malaysia (HUSM)Kota Bharu, MalaysiaContact: Amran A Shokri Prof. Dr, master in orthopedicsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Universiti Sains Malaysia
- Trial code
- NCT07323745
- Record updated
- 12 June 2026
- Original description
The goal of this clinical trial is to learn if the Mobithron Advance drug works to treat and slow the progression of osteoarthritis (OA) in patients. It will also learn about the safety and long-term effects of this drug. The main questions it aims to answer are:Read full original descriptionShow less
Long-Term Effects of Mobithron Advance on Knee Osteoarthritis
The goal of this clinical trial is to learn if the Mobithron Advance drug works to treat and slow the progression of osteoarthritis (OA) in patients. It will also learn about the safety and long-term effects of this drug. The main questions it aims to answer are:
* Does long-term administration of Mobithron Advance can modify the progression of knee osteoarthritis with Kellgren-Lawrence grade 1 to 3 in HUSM patients? * Does long term usage of Mobithron Advance has safety profile? Researchers will compare the Mobithron Advance drug to a placebo (a look-alike substance that contains no drug) to see if said drug works to treat OA.
Participants will:
* Undergo pre-study assessment (baseline assessments) during first visit * Take oral Mobithron Advance daily for 1 year * Visit the clinic once at 3 months, 6 months and 12 months intervals from the initial visit for follow up assessments
Inclusion: Males and female patients above 50 years old at the time of recruitment; OA Diagnosis: Patients with one or both knee osteoarthritis according to clinical and radiological criteria of the American College of Rheumatology (ACR); OA Grade: Kellgren Lawrence grade 1-3.
Exclusion: Patients who received steroid injection treatment within the last 3 months or hyaluronic acid injection treatment within the last 6 months; Patients planning for knee surgery within the research period; Patients on pharmacological treatment for osteoarthritis, other than rescue analgesic agent, e.g: glucosamine, chondroitin, oral steroid; History of joint surgery; Contraindications to Mobithron Advance (e.g., known allergies, severe liver or kidney disease); Secondary arthritis (e.g., rheumatoid arthritis, psoriatic arthritis).